前列腺癌冷冻治疗、射波刀或主动整体监测后的患者报告生活质量进展
研究回顾性分析279例接受射波刀、冷冻治疗或主动整体监测的前列腺癌患者,每3个月收集生活质量问卷,按年分析4年内功能评分。射波刀组早期肠道习惯评分较低(第2年平均差-5.4,P<0.01),但第4年恢复至AHS水平;两组性功能早期较低(射波刀第1年-26.7,冷冻-35.4,均P<0.001),第3年与AHS无显著差异;泌尿功能无差异。
要点
- 射波刀与冷冻治疗组泌尿功能评分与主动整体监测组无差异。
- 射波刀组早期肠道习惯评分较低,第4年恢复至AHS水平。
- 两组性功能早期较低,第3年与AHS无显著差异。
核心结论
- 射波刀或冷冻治疗患者初期肠道习惯和性功能评分较低,但之后与主动整体监测患者无显著生活质量差异。
研究设计与样本
- IRB批准的机构数据库回顾性审查接受射波刀、冷冻治疗或主动整体监测的患者,每3个月收集生活质量问卷,按年分析治疗后4年功能评分,共279例患者(767套问卷)。
主要发现
- 各组间泌尿功能评分无差异。
- 射波刀组治疗后早期肠道习惯评分显著较低(第2年平均差-5.4,P<0.01),但第4年恢复至AHS水平。
- 冷冻治疗组肠道功能评分初期较低但无统计学显著性,之后改善并接近AHS。
- 射波刀组(第1年平均差-26.7,P<0.001)和冷冻治疗组(-35.4,P<0.001)早期性功能评分较AHS低,但逐渐改善,治疗后第3年与AHS无显著差异。
- 有激素治疗史者性功能评分较低:射波刀组(-18.45,P<0.01)和冷冻治疗组(-14.6,P<0.05)。
临床怎么用
- 射波刀和冷冻治疗在器官局限前列腺癌管理中显示获益。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Technological advancements have led to the success of minimally invasive treatment modalities for prostate cancer such as CyberKnife and Cryotherapy. Here, we investigate patient-reported urinary function, bowel habits, and sexual function in patients following CyberKnife (CK) or Cryotherapy treatment, and compare them with active holistic surveillance (AHS) patients. METHODS: An IRB-approved institutional database was retrospectively reviewed for patients who underwent CK, Cryotherapy, or AHS. Quality of life (QoL) survey responses were collected every three months and the mean function scores were analyzed in yearly intervals over the 4 years post-treatment. RESULTS: 279 patients (767 survey sets) were included in the study. There was no difference among groups in urinary function scores. The CyberKnife group had significantly lower bowel habit scores in the early years following treatment (year 2 mean difference: -5.4, P < 0.01) but returned to AHS level scores by year 4. Cryotherapy patients exhibited initially lower, but not statistically significant, bowel function scores, which then improved and approached those of AHS. Both CyberKnife (year 1 mean difference: -26.7, P < 0.001) and Cryotherapy groups (-35.4, P < 0.001) had early lower sexual function scores relative to AHS, but then gradually improved and were not significantly different from AHS by the third year post-treatment. A history of hormonal therapy was associated with a lower sexual function scores relative to those patients who did not receive hormones in both CyberKnife (-18.45, P < 0.01) and Cryotherapy patients (-14.6, P < 0.05). CONCLUSIONS: After initial lower bowel habits and sexual function scores, CyberKnife or Cryotherapy-treated patients had no significant difference in QoL relative to AHS patients. These results highlight the benefit of CyberKnife and Cryotherapy in the management of organ-confined prostate cancer.
引用
- Werneburg GT, Kongnyuy M, Halpern DM, et al. Patient-reported quality of life progression in men with prostate cancer following primary cryotherapy, cyberknife, or active holistic surveillance. Prostate Cancer Prostatic Dis. 2017. PMID: 29217830. doi:10.1038/s41391-017-0004-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。